Mateon reports interim Phase II/III data for Zybrestat in ovarian cancer

Mateon Therapeutics Inc. (OTCQX:MATN) reported data from a second scheduled interim analysis of the first 40 patients with platinum resistant ovarian cancer in the Phase II/III FOCUS trial of Zybrestat fosbretabulin (combretastatin A4P, CA4P) to treat platinum-resistant ovarian cancer. The interim data showed that 60 mg/m² Zybrestat given every 2 weeks plus physician’s choice of chemotherapy and Avastin bevacizumab led to a median progression-free survival (PFS), the primary endpoint, of 6.6 months vs. 5 months for placebo plus chemotherapy and Avastin (HR=0.68; p=0.456). The analysis included the first 40 patients who have been treated for ≥2 months or discontinued the trial.

In 16 evaluable patients in the Zybrestat arm, there were 4 partial responses and 9 cases of stable disease. In 19 evaluable patients in the placebo arm, there were 6 partial responses and 11 cases of stable disease...